Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)
Peter O’Gorman, Jacob P. Laubach, Ruth Clifford, Clifton C. Mo, Senthil Kumar, Omar Nadeem, Monique Hartley-Brown, Siobhan Glavey, Shonali Midha, Yuxin Liu, Maja Ølholm Vase, Keith W. Pratz, Patrick Hayden, Jessica Liegel, Paul Dowling, Emelia Benjamin, Vicky Donachie, Zahra Beers, Olivia McLoughlin, Layla Horwitz, Jacinta Marron, Emma Sueiro, Marc Nolan, David Poretsky, Anna Shevlin, Sarah J. Beaton, C. Prior, C. Piper, Bindu Krishnanivas, Emily J. Simpson, Ebrahim Karimi, Marissa Davis, Lourdes del Rosario McAlester, Amanda Allen, Paul Richardson (2025). Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI). , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-4030.
